The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez, +16

Nature

Gastrointestinal OncologyMedicineHer2 BlockadeImmunologyGastroenterology +7

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

Stephen I. Rudnick, Jianlong Lou, Calvin Shaller, +5

Cancer Research

Immunocytochemical TechniqueNanotherapeuticsSolid TumorsImmunologyImmunotherapeutics +20

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer

Jianming Xu, Haiping Jiang, Yueyin Pan, +28

JAMA

Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis

Hạixia Chen, Jianming Wu, Zhihong Zhang, +2

Frontiers in Pharmacology

MALAT1 Modulates TGF-β1-Induced Endothelial-to-Mesenchymal Transition through Downregulation of miR-145

Xiang Yin, Yachen Zhang, Yong Tang, +1

Cellular Physiology and Biochemistry

Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format

Lillian Shahied, Yong Tang, R. Katherine Alpaugh, +3

Journal of Biological Chemistry

Cancer ImmunosurveillanceMedicineImmunologyMonoclonal AntibodiesParent Minibody +11

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

Wu‐tong Ju, Ronghui Xia, Dongwang Zhu, +17

Nature Communications

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.

Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez, +16

Journal of Clinical Oncology

Jun 17Esophageal CancerCancer ManagementImmunologyGastroenterology +19

The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination

Ren-Huan Xu, Matthew E. Cohen, Yong Tang, +5

The Journal of Experimental Medicine

Viral PathogenesisImmunologyImmunotherapyEffective TargetVaccine Target +14

Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in <i>HER2</i>-Mutant Lung Adenocarcinoma

Wenfeng Fang, Shen Zhao, Ying Liang, +14

The Oncologist